Neutron Delay Extends to 2027; Iridium Deal Emerges as Key 2027 Catalyst

What happened

Rocket Lab's Neutron medium-lift rocket has slipped again, with reports indicating the first launch may not occur until 2027, beyond the prior target of pad delivery in Q4 2026. This setback reinforces management's earlier warning that the window for an end-2026 launch was narrowing and delays the company's entry into the crucial medium-lift market. Meanwhile, the article highlights that the more important 2027 date is the expected acquisition of Iridium Communications, which would add a satellite communications business but also substantial debt and potential equity dilution. The simultaneous occurrence of Neutron delay and Iridium closing means Rocket Lab will need to fund concurrent development and integration costs, straining its balance sheet and execution bandwidth. As a result, the near-term investment case now hinges more on financing discipline and Iridium value creation than on Neutron's initial flight.

Implication

The Neutron slip to 2027 reduces the probability of medium-lift revenue contribution in the next 12-18 months, making the launch segment largely dependent on Electron and HASTE for near-term growth. The Iridium acquisition, if it closes in 2027, will likely require significant debt and equity issuance, diluting existing shareholders and competing for capital with Neutron development. Until permanent financing terms are disclosed, the company's current $2.4 billion liquidity cushion cannot be viewed as a margin of safety because it may be pre-committed to the deal. Investors should demand concrete milestones: completion of Neutron first-stage qualification, a firm launch date, and an Iridium financing structure that does not impair the core rocket program. Given the stock's premium valuation, even a small additional delay or a dilutive financing announcement could trigger a sharp de-rating.

Thesis delta

The investment thesis weakens as the Neutron timeline slips into 2027, confirming that the company will not achieve medium-lift flight in the near term and will continue to burn cash on development. The Iridium acquisition adds a new layer of risk: while it may diversify revenue, the financing structure and integration challenges could erode per-share value and distract management. The WAIT rating remains appropriate, with a more attractive entry below $52 or after first-stage qualification and permanent financing clarity.